Loading
A phase 2 trial of Ivonescimab, Cadonilimab, AK117 in small-cell lung cancer, run by Akeso, now recruiting.
A Study of Ivonescimab in First-Line ES-SCLC is a phase 2 interventional study registered as NCT07245446 by Akeso, with 180 participants planned, started 2025-10-29 and due to reach its primary completion in 2027-12. Interventions recorded: Ivonescimab, Cadonilimab, AK117, Etoposide, Carboplatin (AUC 5). Conditions listed: Extensive-stage Small Cell Lung Cancer (ES-SCLC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Akeso, Ivonescimab, Bispecific antibodies, Carboplatin.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Akeso, Ivonescimab, Bispecific antibodies, Small-cell lung cancer.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Akeso, Ivonescimab, Bispecific antibodies, Small-cell lung cancer.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/